advances in cholestatic liver diseases an issue o

rather than curative. Early diagnosis: Need for sensitive, specific biomarkers for preclinical detection. Understanding pathogenesis: Further elucidation needed to develop targeted therapies. Future directions include: Development of novel receptor modulators and gene therapie